İlhami Kiki
Atatürk University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by İlhami Kiki.
Brain Research | 2005
Bunyami Unal; Hüseyin Tan; Zerrin Orbak; İlhami Kiki; Mehmet Bilici; Nizamettin Bilici; Hüseyin Aslan; Süleyman Kaplan
Zinc (Zn) is an essential trace element for humans and animals. It is required for normal growth, gene expression, wound healing, protein metabolism, immune function, and membrane integrity. In this study, unbiased stereological methods have been used to quantify the effects of Zn deficiency on the sectioned surface area and the number of myelinated axons in the sciatic nerve of rats. Animals were fed a Zn-deficient or Zn-sufficient diet for a period of 4 weeks. At the end of this time, the samples of sciatic nerves were removed from the animals, processed for electron microscopy and embedded in resin. The Zn-deficient group of rats was found to have a lower body weight compared to rats in the control group (P < 0.05). The sectioned surface area of nerve cross-section and myelinated axon number in Zn-deficient rats decreased by 20% and 29%, respectively, compared to the control group. A significant correlation between sectioned surface area and myelinated axon number was also determined. Morphological findings were as follows: on light microscopy, it was determined that certain abnormalities occur specifically in the experimental group, such as collapsed nerve fascicles, irregular profiles of and degeneration in myelin sheaths, and on electron microscopy, extensive myelin damage was seen in Zn-deficient groups compared with control groups. This study suggests that peripheral nerves require Zn for development and preservation of their structure.
The American Journal of the Medical Sciences | 2008
İlhami Kiki; Mehmet Gundogdu; Bulent Albayrak; Yilmaz Bilgiç
Thrombotic thrombocytopenic purpura (TTP) is characterized by disseminated thrombotic occlusions located in the microcirculation and a syndrome of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, fever, and renal and neurologic abnormalities. Although several factors such as viral and bacterial pathogens, pancreatitis, drugs, collagen-vascular diseases, cancers, and pregnancy have been reported to be associated with TTP, brucellosis is an exceptional cause of this disorder. We represent a 19-year-old woman applying to our outpatient department with the complaints of headache, fever, sweat, malaise, and jaundice. Clinical signs and laboratory findings were consistent with TTP. Brucella agglutination was found to be 1/320 positive. After the administration of therapeutic plasma exchange, all symptoms and laboratory abnormalities improved dramatically. Antibiotic therapy directed to Brucella infection was initiated and no recurrence of TTP was seen.
Medical Principles and Practice | 2007
Fuat Erdem; İlhami Kiki; Mehmet Gundogdu; Hasan Kaya
Objective: To report a case of brucella infection presenting with thrombotic thrombocytopenic purpura (TTP) that responded well to plasma and antimicrobial treatment infusion. Case Presentation and Intervention: A 51-year-old man with moderate confusion, depressed mood and dysarthria was admitted. He was chronically ill, with fever (38.5°C), anemia, jaundice and petechial-purpuric skin lesions. Neurological examination revealed diminished consciousness with a Glasgow coma scale score of 7 and +1 neck rigidity. The hemoglobin and platelet counts were decreased and reticulocyte index, erythrocyte sedimentation rate, as well as serum lactate dehydrogenase and renal dysfunction were elevated. TTP was a possible diagnosis and the patient responded well to plasma infusion and antimicrobial treatment. Conclusion: This report shows that therapy of underlying infection together with plasma infusion may be a successful treatment option for brucellosis-induced TTP.
International Journal of Clinical Practice | 2006
İlhami Kiki; O. Yilmaz; Fuat Erdem; Mehmet Gundogdu; B. Demircan; Mehmet Bilici
Although both chronic active hepatitis‐B (CAH‐B) and liver cirrhosis (LC) are characterised by various degrees of inflammation and hepatocyte necrosis, in advanced stage cirrhosis, marked fibrosis develops and inflammation and tissue necrosis diminishes.
Transfusion and Apheresis Science | 2012
Serdal Korkmaz; Muzaffer Keklik; Serdar Sivgin; Rahsan Yildirim; Anil Tombak; Mehmet Emin Kaya; Didar Yanardag Acik; Ramazan Esen; Sibel Hacioglu; Mehmet Sencan; İlhami Kiki; Eyup Naci Tiftik; Irfan Kuku; Vahap Okan; Mehmet Yilmaz; Cengiz Demir; Ismail Sari; Ali Unal; Osman Ilhan
UNLABELLED Thrombotic thrombocytopenic purpura (TTP) is a particular form of thrombotic microangiopathy typically characterized by thrombocytopenia, microangiopathic hemolytic anemia, fever, neurological abnormalities, and renal dysfunction. TTP requires a rapid diagnosis and an adapted management in emergency. Daily sessions of therapeutic plasma exchange (TPE) remain the basis of management of TTP. Also, TTP is a rare disease that is fatal if it is not treated. TPE has resulted in excellent remission and survival rates in TTP patients. AIM We aimed to present our experience in 163 patients with TTP treated with TPE during the past 5years from 10 centers of Turkey. PATIENTS AND METHODS One hundered and sixty-three patients with TTP treated with TPE during the past 5years from 10 centers of Turkey were retrospectively evaluated. TPE was carried out 1-1.5times plasma volume. Fresh frozen plasma (FFP) was used as the replacement fluid. TPE was performed daily until normalization of serum lactate dehydrogenase (LDH) and recovery of the platelet count to >150×10(9)/dL. TPE was then slowly tapered. Clinical data, the number of TPE, other given therapy modalities, treatment outcomes, and TPE complications were recorded. RESULTS Fifty-eight percent (95/163) of the patients were females. The median age of the patients was 42years (range; 16-82). The median age of male patients was significantly higher than female (53 vs. 34years; p<0.001). All patients had thrombocytopenia and microangiopathic hemolytic anemia. At the same time, 82.8% (135/163) of patients had neurological abnormalities, 78.5% (128/163) of patients had renal dysfunction, and 89% (145/163) of patients had fever. Also, 10.4% (17/163) of patients had three of the five criteria, 10.4% (17/163) of patients had four of the five criteria, and 6.1% (10/163) of patients had all of the five criteria. Primary TTP comprised of 85.9% (140/163) of the patients and secondary TTP comprised of 14.1% (23/163) of the patients. Malignancy was the most common cause in secondary TTP. The median number of TPE was 13 (range; 1-80). The number of TPE was significantly higher in complete response (CR) patients (median 15.0 vs. 3.5; p<0.001). CR was achieved in 85.3% (139/163) of the patients. Similar results were achieved with TPE in both primary and secondary TTP (85% vs. 87%, respectively; p=0.806). There was no advantage of TPE+prednisolone compared to TPE alone in terms of CR rates (82.1% vs. 76.7%; p=0.746). CR was not achieved in 14.7% (24/163) of the patients and these patients died of TTP related causes. There were no statistical differences in terms of mortality rate between patients with secondary and primary TTP [15% (21/140) vs. 13% (3/23); p=0.806]. But, we obtained significant statistical differences in terms of mortality rate between patients on TPE alone and TPE+prednisolone [14% (12/86) vs. 3% (2/67), p<0.001]. CONCLUSIONS TPE is an effective treatment for TTP and is associated with high CR rate in both primary and secondary TTP. Thrombocytopenia together with microangiopathic hemolytic anemia is mandatory for the diagnosis of TTP and if these two criteria met in a patient, TPE should be performed immediately.
Clinical and Applied Thrombosis-Hemostasis | 2014
Ibrahim Halil Tanboga; Selim Topcu; Tuncer Nacar; Enbiya Aksakal; Kamuran Kalkan; İlhami Kiki; Serdar Sevimli
Objectives: We aimed to investigate the relationship between red cell distribution width (RDW) value and coronary collateral circulation (CCC) in patients with non-ST elevation myocardial infarction (NSTEMI). Methods: The study population consisted of 322 consecutive patients with NSTEMI. The patients were classified into impaired CCC (group 1, Rentrop grades 0-1) or good CCC (group 2, Rentrop grades 2-3). Baseline RDW was measured as part of the automated complete blood count. Results: The RDW values were significantly higher in patients with impaired CCC than in those with good CCC (17.2 ± 2.3 vs 14.5 ± 2.5, P < .001). In multivariate logistic regression analysis, RDW (odds ratio: 1.52, 95% confidence interval: 1.30-1.78, P < .001), baseline creatine kinase MB (CK-MB), and absence of preinfarction angina were found to be the independent predictors of impaired CCC. In receiver–operating characteristic curve analysis, the RDW value >15.5 yielded an area under curve value of 0.783, with 77% sensitivity and 73% specificity. Conclusions: Our study results demonstrated that, high RDW, high CK-MB, and absence of preinfarction angina were found to be independent predictors of impaired CCC.
Journal of Molecular Histology | 2012
Sare Sipal; Zekai Halici; İlhami Kiki; Beyzagul Polat; Abdulmecit Albayrak; Fatih Albayrak; Emre Karakus; Selina Aksak; Berna Ozturk; Cemal Gundogdu
The presence of liver disease in patients with progressively worsening insulin resistance may not be recognized until patients develop manifestations of the metabolic syndrome such as diabetes, hypertension, hyperlipidemia, and vascular disease. It was aimed to investigate whether three angiotensin II type 1 receptor antagonists (ARBs) (olmesartan, losartan, and valsartan) had preventive effect against hepatic fibrosis and this was a common characteristic among ARBs. In current study, 25 adult male rats were used and divided into five groups: the non-diabetic healthy group, alloxan induced diabetic (AID) control group, AID losartan group, AID valsartan group and AID olmesartan group. According to numerical density of hepatocytes, significant difference was found between the non-diabetic healthy group and diabetic control group. All treatments groups were significant when compared to diabetic control group. In diabetic control group it was examined swelling, irregular cristae arrangement in some of mitochondria. It was also determined mitochondria membrane degeneration in some areas of section profiles. In diabetic rats treated with losartan group, there were necrotic hepatocytes. In diabetic rats treated with valsartan group, predominantly, findings were similar to losartan group. In diabetic rats treated with olmesertan group, plates of hepatocytes were quite regular. There were hardly necrotic cells. Not only other organelles such as RER, SER and lysosom but also mitochondrial structures had normal appearance. In the diabetic control group electron microscopy revealed edema in both the cytoplasm and perinuclear area and the nuclear membranes appeared damaged. In conclusion, it was established that the most protective ARB the liver in diabetic rats was olmesartan, followed by losartan.
Transfusion and Apheresis Science | 2013
Rahsan Yildirim; Mehmet Gundogdu; Aysu Ozbıcer; İlhami Kiki; Fuat Erdem; Hasan Dogan
Acute promyelocytic leukemia (APL) is a specific type of acute myeloid leukemia (AML) and has distinct hematopathologic, cytogenetic, clinical and molecular features. This study was a retrospective review of 18 adult patients (10 male, 8 female; mean age of 32.17 ± 5.66 (15-61 years) with APL at our department from January 2006 to December 2011. Following induction therapy, 17 patients achieved CR, 1 of 18 patients died of result bleeding within thirty-sixth hours of admission. In two of 18 patients developed RAS. The relapse rate was 27% (5/18). Fourteen of 18 patients (77%) have been followed in remission. APL is a malignancy requiring quick diagnosis, efficient treatment and supportive care system. ATO, one of the important therapy option in the treatment of APL, cannot be obtained easily in developing countries. This may lead to an increase in the mortality rates. The studies should be made with more number of patients and a longer period of time for accurate results.
Turkish Journal of Biochemistry-turk Biyokimya Dergisi | 2015
İlhami Kiki; Rahsan Yildirim; Abdulkadir Yildirim; Esra Laloglu; Kenan Cadırcı; Fuat Erdem; Mehmet Gundogdu
Abstract Objective: The aim of the present study was to investigate whether the VKORC1 -1639 G>A polymorphisms could determine differences in the warfarin dose required to maintain a therapeutic INR in patients living in east of Turkish. Methods: A total of 80 patients (45 female and 35 male) aged between 17 and 85 years (mean age 58.96±16.59 years) using warfarin for at least one month and presenting at Atatürk University Medical Faculty Outpatient Clinic between May 2009 and May 2010 were included in the study. Patients underwent genotype investigations and carrier forms of VKORC1 -1639 variants; homozygous (AA), heterozygous (GA) and wild types (GG) were determined. Results: In AA and GA groups, daily warfarin maintenance doses were statistically significant lower than in GG (p=0.010 and p=0.016, respectively). There was no significant difference between AA and GA groups regarding to warfarin dose (p>0.05). INR values were higher in GA and AA groups than in GG group and differences were statistically significant (p=0.014 and p=0.016, respectively). Also there was no difference between GA and AA gropus in terms of INR. Conclusion: In conclusion, our study verified the interindividual variability in warfarin maintenance dose due to VKORC1-1639 G>A polymorphism in patients living in east of Turkish. In order to avoid serious bleeding events in warfarin therapy, prescription of warfarin should be done on an individual basis with consideration for the patient’s genetic background. Özet Amaç: Çalışmanın amacı Türkiye’nin doğusunda yaşayan hastalarda, tedavi edici INR seviyesine ulaşmak için gerekli warfarin dozunun VKORC1 -1639 G>A polimorfizmine göre değişiklik gösterip göstermediğini tespit etmekti. Metod: Çalışma kapsamına Atatürk Üniversitesi Tıp Fakültesi İç Hastalıkları Polikliniği’ne Mayıs 2009 ve Mayıs 2010 yılları arasında yaşları 17-85 arasında olan (ortalama yaş 58.96±16.59 yıl) ve en az bir ay süre ile warfarin kullanan, 45’i kadın ve 35’i erkek, toplam 80 hasta alındı. VKORC1 -1639 G>A polimorfizmi için genetik araştırma yapıldı ve bu genin varyantları; homozigot (AA), heterozigot (GA) ve wild tip (GG) olması açısından değerlendirildi. Bulgular: Günlük warfarin idame dozu, AA ve GA grubunda GG grubundan istatistiksel olarak anlamlı düşüktü (sırasıyla p=0.004 ve p=0.017). AA ve GA grubu arasında warfarin dozu açısından anlamlı farklılık yoktu (p>0.05). GA ve AA gruplarında, INR değerleri GG grubuna göre daha yüksekti ve farklılıklar istatistiki olarak anlamlı idi (sırası ile p=0.014 ve p=0.016). Ayrıca INR değeri açısından GA ve AA grupları arasında farklılık yoktu. Sonuç: Sonuç olarak çalışmamız; Türkiye’nin doğusunda yaşayan hastalarda, VKORC1-1639 G>A polimorfizmi nedeni ile warfarin idame dozları arasında bireysel farklılık olduğunu doğruladı. Warfarin tedavisine bağlı oluşan şiddetli kanamaları önlemek için tedaviye başlamadan önce hastanın genetik yapısına göre kişiye özel warfarin dozunu belirlemek gerekir.
The Eurasian Journal of Medicine | 2011
Zulal Ozkurt; Kemalettin Özden; İlhami Kiki; Mustafa Usanmaz
OBJECTIVE Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne viral hemorrhagic fever. Disseminated intravascular coagulation (DIC) is an important complication of this disease, especially in severe and fatal cases. Antithrombin (AT) acts as an anticoagulant by inactivating thrombin, Factor IX, Factor X and Factor XI. We conducted this study to investigate the AT levels and their prognostic value in CCHF. MATERIALS AND METHODS Twenty-eight confirmed CCHF patients were included in this study. Diagnosis of the disease was made by CCHF IgM and/or PCR positivity. Patients were grouped based on the severity criteria described previously. The patients with platelet counts <20 000×10(6) cell/L, white blood counts >10×10(9) cell/L, prothrombin times >60 seconds, aspartate aminotransferase levels >700 IU/L or alanine aminotransferase levels >900 IU/L were accepted as severe cases. Patients whose illnesses were self-limited and who did not require blood component replacement were accepted as mild cases, and patients who improved but required blood component replacement were accepted as moderate cases. Blood samples were obtained on the day that the patient had the lowest platelet count and before any thrombocyte replacement. The antithrombin activity was measured using a chromogenic substrate test (Diagnostica Stago STA Compact) at a research laboratory. RESULTS Twenty-two (78.6%) of the cases were mild, 3 (10.7%) were moderate, and 3 were (10.7%) severe. The mean AT value was 101% for mild cases, 116.6 % for moderate cases, and 88% for severe cases (p>0.05). Although there were no statistically significant differences between the AT values, the mean AT activity was lower in severe CCHF cases. CONCLUSION The AT activity may have been decreased in severe CCHF cases. Further studies with greater numbers of patients are required to determine the level of AT activity and its correlation with disease severity and the prognosis of CCHF.